157 related articles for article (PubMed ID: 36972796)
1. Single-cell atlas of the liver myeloid compartment before and after cure of chronic viral hepatitis.
Cui A; Li B; Wallace MS; Gonye ALK; Oetheimer C; Patel H; Tonnerre P; Holmes JA; Lieb D; Yao BS; Ma A; Roberts K; Damasio M; Chen JH; Piou D; Carlton-Smith C; Brown J; Mylvaganam R; Hon Fung JM; Sade-Feldman M; Aneja J; Gustafson J; Epstein ET; Salloum S; Brisac C; Thabet A; Kim AY; Lauer GM; Hacohen N; Chung RT; Alatrakchi N
J Hepatol; 2024 Feb; 80(2):251-267. PubMed ID: 36972796
[TBL] [Abstract][Full Text] [Related]
2. Unraveling the role of the liver myeloid compartment during hepatitis C virus cure.
Crouchet E; Baumert TF
J Hepatol; 2024 Feb; 80(2):184-187. PubMed ID: 37088307
[No Abstract] [Full Text] [Related]
3. Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses.
Aregay A; Owusu Sekyere S; Deterding K; Port K; Dietz J; Berkowski C; Sarrazin C; Manns MP; Cornberg M; Wedemeyer H
J Hepatol; 2019 Nov; 71(5):889-899. PubMed ID: 31295532
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals.
Perez S; Kaspi A; Domovitz T; Davidovich A; Lavi-Itzkovitz A; Meirson T; Alison Holmes J; Dai CY; Huang CF; Chung RT; Nimer A; El-Osta A; Yaari G; Stemmer SM; Yu ML; Haviv I; Gal-Tanamy M
PLoS Genet; 2019 Jun; 15(6):e1008181. PubMed ID: 31216276
[TBL] [Abstract][Full Text] [Related]
5. Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection.
Casey JL; Feld JJ; MacParland SA
Cells; 2019 Apr; 8(4):. PubMed ID: 30959825
[TBL] [Abstract][Full Text] [Related]
6. Effect of Direct Acting Antivirals (DAAs) on Myeloid-Derived Suppressor Cells Population in Egyptian Chronic Hepatitis C Virus Patients: A Potential Immunomodulatory Role of DAAs.
Abdulsamad B; Afifi M; Awaad AK; Elbendary W; Mustafa H; Elsherbini B
Viral Immunol; 2023 May; 36(4):259-267. PubMed ID: 36802279
[TBL] [Abstract][Full Text] [Related]
7. Intrahepatic immune changes after hepatitis c virus eradication by direct-acting antiviral therapy.
Amaddeo G; Nguyen CT; Maillé P; Mulé S; Luciani A; Machou C; Rodrigues A; Regnault H; Mallat A; Laurent A; Lafdil F; Hézode C; Pawlotsky JM; Calderaro J
Liver Int; 2020 Jan; 40(1):74-82. PubMed ID: 31444947
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study.
Flower B; Hung LM; Mccabe L; Ansari MA; Le Ngoc C; Vo Thi T; Vu Thi Kim H; Nguyen Thi Ngoc P; Phuong LT; Quang VM; Dang Trong T; Le Thi T; Nguyen Bao T; Kingsley C; Smith D; Hoglund RM; Tarning J; Kestelyn E; Pett SL; van Doorn R; Van Nuil JI; Turner H; Thwaites GE; Barnes E; Rahman M; Walker AS; Day JN; Chau NVV; Cooke GS
Elife; 2023 Jan; 12():. PubMed ID: 36622106
[TBL] [Abstract][Full Text] [Related]
9. Reverse inflammaging: Long-term effects of HCV cure on biological age.
Oltmanns C; Liu Z; Mischke J; Tauwaldt J; Mekonnen YA; Urbanek-Quaing M; Debarry J; Maasoumy B; Wedemeyer H; Kraft ARM; Xu CJ; Cornberg M
J Hepatol; 2023 Jan; 78(1):90-98. PubMed ID: 36152762
[TBL] [Abstract][Full Text] [Related]
10. HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients.
Brochado-Kith Ó; Martínez I; Berenguer J; González-García J; Salgüero S; Sepúlveda-Crespo D; Díez C; Hontañón V; Ibañez-Samaniego L; Pérez-Latorre L; Fernández-Rodríguez A; Ángeles Jiménez-Sousa M; Resino S
Front Immunol; 2021; 12():723196. PubMed ID: 34497613
[TBL] [Abstract][Full Text] [Related]
11. Innate and adaptive immune responses in HCV infections.
Heim MH; Thimme R
J Hepatol; 2014 Nov; 61(1 Suppl):S14-25. PubMed ID: 25443342
[TBL] [Abstract][Full Text] [Related]
12. Immunological Analysis During Interferon-Free Therapy for Chronic Hepatitis C Virus Infection Reveals Modulation of the Natural Killer Cell Compartment.
Spaan M; van Oord G; Kreefft K; Hou J; Hansen BE; Janssen HL; de Knegt RJ; Boonstra A
J Infect Dis; 2016 Jan; 213(2):216-23. PubMed ID: 26223768
[TBL] [Abstract][Full Text] [Related]
13. Achieving a high cure rate with direct-acting antivirals for chronic Hepatitis C virus infection in Cameroon: a multi-clinic demonstration project.
Coyer L; Njoya O; Njouom R; Mossus T; Kowo MP; Essomba F; Boers A; Coutinho R; Ondoa P;
Trop Med Int Health; 2020 Sep; 25(9):1098-1109. PubMed ID: 32502290
[TBL] [Abstract][Full Text] [Related]
14. Rapid hepatitis C virus clearance by antivirals correlates with immune status of infected patients.
Sasaki R; Meyer K; Moriyama M; Kato N; Yokosuka O; Ray RB; Aurora R; Ray R; Kanda T
J Med Virol; 2019 Mar; 91(3):411-418. PubMed ID: 30192392
[TBL] [Abstract][Full Text] [Related]
15. Assessment of factors affecting response of direct-acting antivirals in chronic hepatitis C patients.
Jain N; Garg R; Singh GP; Kaur S; Chawla SPS; Padda P
Ann Afr Med; 2023; 22(4):456-464. PubMed ID: 38358146
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C Virus and the Host: A Mutual Endurance Leaving Indelible Scars in the Host's Immunity.
Mondelli MU; Ottolini S; Oliviero B; Mantovani S; Cerino A; Mele D; Varchetta S
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203436
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus-specific immune responses following direct-acting antivirals administered during recent hepatitis C virus infection.
Casey JL; Dore GJ; Grebely J; Matthews GV; Cherepanov V; Martinello M; Marks P; Janssen HLA; Hansen BE; Kaul R; MacParland SA; Gehring AJ; Feld JJ
J Viral Hepat; 2023 Jan; 30(1):64-72. PubMed ID: 36302162
[TBL] [Abstract][Full Text] [Related]
18. [Immunology of HCV infection: the causes of impaired cellular immune response and the effect of antiviral treatment].
Pár G; Berki T; Pálinkás L; Balogh P; Szereday L; Halász M; Szekeres-Barthó J; Miseta A; Hegedus G; Mózsik G; Hunyady B; Pár A
Orv Hetil; 2006 Apr; 147(13):591-600. PubMed ID: 16623441
[TBL] [Abstract][Full Text] [Related]
19. Memory re-differentiation and reduced lymphocyte activation in chronic HCV-infected patients receiving direct-acting antivirals.
Burchill MA; Golden-Mason L; Wind-Rotolo M; Rosen HR
J Viral Hepat; 2015 Dec; 22(12):983-91. PubMed ID: 26482547
[TBL] [Abstract][Full Text] [Related]
20. Dynamic changes in innate immune responses during direct-acting antiviral therapy for HCV infection.
Holmes JA; Carlton-Smith C; Kim AY; Dumas EO; Brown J; Gustafson JL; Lauer GM; Silva ST; Robidoux M; Kvistad D; Alatrakchi N; Tonnerre P; Cohen DE; Zhang H; Shulman NS; Chung RT
J Viral Hepat; 2019 Mar; 26(3):362-372. PubMed ID: 30450781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
